Bavarian Nordic to Acquire Portfolio of Travel Vaccines from Emergent BioSolutions
On February 15, Bavarian Nordic announced that it has entered into an agreement with Emergent BioSolutions Inc. to acquire two marketed travel vaccines.
The vaccines included in the acquisition are Vivotif for typhoid fever prevention, Vaxchora for cholera prevention, and a phase 3 vaccine candidate for the prevention of chikungunya virus.
The deal also includes a manufacturing facility in Switzerland, a research and development facility in the U.S., and EU and U.S.-based commercial operations.
The acquisition will strengthen its position in the travel vaccine market and reinforce its pipeline with a late-stage vaccine candidate against chikungunya, which is an emerging infectious disease that represents a significant unmet medical need worldwide.